Please assess the completion status of the following clinical trial:

Trial Title: Low-dose IL-2( Interleukin-2) Treatment in SLE

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the American College of Rheumatology criteria for the diagnosis of SLE.~* Under standard treatment (≥ 2 months) at the time of inclusion~* Background treatment failed to control flares or to permit prednisone tapering~* With at least one of the following manifestations: thrombocytopenia, disease-associated rash, mouth ulcer, non-infectious type of fever, active vasculitis, renal disorder(proteinuria\>0.5g/day), neuropsychiatric SLE.~* Positive for at least one of the following laboratory tests: ANA\>1:160, anti-dsDNA, immunoglobulin\>20g/L, decreased C3 or C4, leukopenia\<3×10\^9/L, thrombocytopenia\<100×10\^9/L;~* SLE disease activity index(SLEDAI) ≥ 8.~* Negative HIV test.~* Negative for hepatitis B and C virus.~* Written informed consent form.~Exclusion Criteria:~* Sever chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade III NYHA), hepatic insufficiency (transaminases\> 3N) )~* Serious infection such as bacteremia, sepsis;~* Cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or Basocellular carcinoma);~* High-dose steroid pulse therapy (\>1.5mg/kg) or IV bolus of corticosteroids in the last 2 months.~* History of administration of rituximab or other biologics;~* Purified protein derivative (tuberculin) \>10mm~* Mental disorder or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give information;~* Inability to comply with IL-2 treatment regimen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Interleukin-2 (Type: EXPERIMENTAL): Interleukin-2 to treat activated SLE.

Based on this trial design, predict the completion outcome and termination type (if applicable).